New Age Alpha Advisors LLC Makes New $1.35 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

New Age Alpha Advisors LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 28,264 shares of the biopharmaceutical company's stock, valued at approximately $1,351,000.

Other large investors have also added to or reduced their stakes in the company. Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at $69,000. Retirement Systems of Alabama boosted its holdings in shares of Halozyme Therapeutics by 23.5% during the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock worth $22,282,000 after buying an additional 74,173 shares during the period. Shaker Investments LLC OH grew its stake in Halozyme Therapeutics by 12.3% in the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock valued at $3,601,000 after buying an additional 8,249 shares during the last quarter. Foster & Motley Inc. lifted its position in Halozyme Therapeutics by 118.6% during the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock worth $1,113,000 after acquiring an additional 12,630 shares during the last quarter. Finally, Jennison Associates LLC acquired a new stake in Halozyme Therapeutics during the fourth quarter worth approximately $731,000. Institutional investors own 97.79% of the company's stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,200 shares of company stock worth $1,786,668 over the last three months. Corporate insiders own 2.90% of the company's stock.

Remove Ads

Halozyme Therapeutics Price Performance

HALO stock traded down $2.15 during midday trading on Friday, reaching $59.77. The company had a trading volume of 2,295,325 shares, compared to its average volume of 1,392,933. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The stock has a 50 day moving average price of $59.82 and a 200-day moving average price of $54.93. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The company has a market capitalization of $7.38 billion, a price-to-earnings ratio of 17.43, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Benchmark reissued a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.